Karin Hellsvik

Bio:

Karin Hellsvik is Vice President, Corporate Affairs, Investor Relations and Operations, at Foghorn Therapeutics, a clinical-stage biotechnology company advancing first-in-class precision oncology medicines. Previously, Karin spent more than a decade at Biogen, most recently as Executive Director and Head of Corporate Affairs for the global Alzheimer’s business, where she led communications, media relations, patient advocacy, and external engagement during periods of heightened scrutiny and change. Before this, she spent four years at Biogen’s international headquarters in Switzerland, where she built the company’s Patient Advocacy function. She also served as Biogen’s Head of Patient Communications in the Nordic region, based in Denmark.

Earlier in her career, Karin spent nearly a decade advising a broad range of clients on pharmaceutical communications and advocacy at leading Nordic healthcare communications agencies. She holds an educational background in communications from Sweden and deepened her understanding of global healthcare and disparities through the MGH Disparities Leadership Program at the Mongan Institute Health Policy Research Center in Boston.

She serves on the boards of UsAgainstAlzheimer’s, BioTech Social and Epoch Biotech, reflecting a long-standing commitment to patients and to strengthening the broader biotech ecosystem.